Servier China

The celebrations for Servier's 70th anniversary kicked off at #ServierChina! In honor of this significant occasion, 500 employees across 6 offices nationwide crafted mooncakes adorned with patterns representing iconic landmarks from each city and 70 years, commemorating our seven decades of excellence，spreading joy and happiness of this moment. Just as the mooncake is a traditional symbol of unity and prosperity in Chinese culture, the collaborative effort of crafting each mooncake with love signifies unity within diversity and our shared aspirations for a healthier tomorrow. Let's continue to foster a future where healthcare pushes boundaries, and everyone has access to the treatments they need. Here's to 70 years of success and many more to come! 施维雅中国庆祝施维雅集团成立70周年的活动正式开启！ 为了庆祝这一重要的里程碑，中国6个办公室的500名员工“一起造月”，制作了装饰着“70周年”字样和各城市地标图案的月饼，以纪念集团七十年来的卓越成就，传递欣喜与幸福。 月饼在中国文化中象征团结与繁荣，用爱精心制作的月饼象征着团结中蕴含的多样性，以及对更健康明天的憧憬。让我们继续努力，不断扩展医疗的边界，让每个人都能获得所需的治疗。为过去的70年的成就干杯，并期待更美好的未来！ #WeAreServier #MovedByYou #DareToCake

99 Giving Day is a special day every year on Sept.9 to celebrate as one of the largest public welfare festivals in the world. We are honored to welcomed Chinese Organization for Rare Disorders, clinical expert, patient groups and media to Servier's office in Beijing. At this workshop organized to know about the glioma, a rare and hard-to-treat cancer, all the speakers and participants shared their stories and views around patient needs and the hope for breakthrough in medical solutions. We are proud that Servier China is part of the united efforts to make a change for the lives suffering from glioma. At #ServierChina, we work closely with medical institutions and patient organizations to push forward the development and application of innovative drugs and provide treatment options for glioma patients. 每一年9月9日是庆祝99公益日的特别的一天。施维雅北京办公室迎来了蔻德罕见病中心、临床专家、患者组织和媒体，共同探讨了解脑胶质瘤这种少见且难治性疾病。到场的嘉宾和参与者分享了他们对抗脑胶质瘤的故事和心得，并表达对突破性治疗方案的期待。我们非常骄傲，施维雅中国与多方力量团结在一起，为身患脑胶质瘤患者的生命带来改变。 施维雅中国将与医疗学会和患者组织紧密合作，推动创新药物的开发和应用，为脑胶质瘤患者提供治疗方案。 让我们聚“胶”生命希望！ #MovedByYou #Glioma #Patient #Oncology

August 19, 2024 marks the seventh Chinese Doctors' Day.   “To cure sometimes, to relieve often, to comfort always.” Doctors are the bedrock of our healthcare system, playing an irreplaceable role in promoting health and well-beings. They not only provide medical support to patients consciously, but also bring love and hope to those who need it most. It's time to say a big THANK YOU to doctors for all the dedication they bring to their professions every day.   Salute to life-saving medics on Chinese Doctors' Day!   2024年8月19日是第七个“中国医师节”。   “偶尔治愈，常常帮助，总是安慰”——医生是一个表达善良、救护病者、体恤痛者、体现人生价值的崇高职业。   医者仁心，救死扶伤。他们为需要帮助的人们带来爱与希望，为增进人类健康福祉发挥不可替代的作用。   感谢每一位医生每一天的辛勤付出与无私奉献！让我们一起向生命守护者致敬！   #ServierChina #MovedByYou

Ensuring patients' access to #ServierChina 's high-quality medication is one of our priorities. From daily medication for cardiovascular diseases to innovative therapies for patients with hard-to-treat cancers, we have been working closely with distribution partners for 45 years to serve Chinese patients, whether at Three A hospitals or Community Health Center. #ServierMoment of today. It's from WANG Ximing from Commercial BU, sharing his thoughts of cooperation with distribution partners. Joining efforts with partners, we safeguard the health of thousands of households in China! 施维雅中国一直致力于提高优质药品的可及性。从心血管疾病的日常用药到难治肿瘤的创新治疗方案，从大城市和三甲医院到基层乡镇卫生医疗服务中心，45年来，我们与经销商伙伴密切合作，服务广大中国患者。 #关于施维雅人的vlog#，来自商务业务部王熙铭分享自己与经销商伙伴的工作心得。携手强大“朋友圈”，共同守护患者健康。 #WeAreServier #MovedByYou #45yearsAnniversary

We are very happy and proud to be certified as #GreatPlaceToWork the third time in a row, affirming our efforts in employer branding. 96.3% of employees saying that #ServierChina is a great place to work. Having rooted in China for 45 years, Servier is committed to continuously cultivating a diverse, inclusive, equitable and compassionate corporate culture, which is an imperative component of the company's strategy and a key driver in achieving our long-term objectives. An outstanding workplace culture plays a vital role in empowering individuals and fostering development. 我们很高兴和自豪地宣布施维雅中国三度蝉联全球职场文化权威机构Great Place To Work®的“卓越职场”认证™。这是施维雅雇主品牌获得的又一个认可。 96.3%参与调研的员工认为，综合各方面的考虑，施维雅中国是一个理想的工作场所。三年来，调查参与度的持续提升，以及所有评估指标得分的不断进步，彰显了施维雅中国为提升职场体验所采取的措施取得了积极的效果。 根植中国45年，施维雅持续打造多元、包容、平等、友爱的企业文化，这是公司战略的重要一环，也是我们实现长期目标的关键。卓越的职场文化对于充分赋能、人才发展具有至关重要的作用。 #GPTW #WeAreServier #MovedByYou

Servier is excited to share a strategic partnership with AmoyDx, a China-based innovative molecular diagnostics company, to develop a companion diagnostic test (CDx) in China that detects Isocitrate Dehydrogenase (IDH) 1&2 gene mutations. This test will be developed for vorasidenib, Servier’s investigational dual inhibitor of mutant IDH1 and mutant IDH2 enzymes, for Chinese patients with diffuse IDH-mutant glioma (LGG). According to Fabien Schmidlin, Global Head of Translational Medicine at Servier: “Early detection of IDH 1 & 2 mutations play a critical role in the treatment of patients suffering from diffuse glioma. The development of a therapy and the associated companion diagnostic test are two parallel highways that are connected to each other providing the right patient with the right treatment faster. The collaboration with AmoyDx will accelerate the development of innovative therapeutics and diagnostic tests, respectively, in order to expand patients' access to medicines, hence improving their treatment outcomes.” Companion diagnostic tests aim to define sub-populations of patients likely to respond favorably to a treatment. Through this partnership, Servier demonstrates its constant ambition to provide patients around the world with better access to precision medicine.   施维雅与中国创新分子诊断公司艾德生物已达成战略合作伙伴关系，在中国共同开发一种伴随诊断（CDx）试剂，用于检测异柠檬酸脱氢酶（IDH）1和2基因突变。该试剂将用于施维雅的研究性新药vorasidenib，这是一款突变型异柠檬酸脱氢酶1和2（IDH1和IDH2）的双重抑制剂，预计在获批之后可用于治疗携带IDH突变的弥漫性脑胶质瘤（LGG）的中国患者。 施维雅全球转化医学负责人Fabien Schmidlin表示：“作为IDH突变肿瘤领域的创新者，我们深信早期检测IDH 1和IDH 2基因突变在治疗弥漫性脑胶质瘤患者中发挥着关键作用。治疗药物和相关伴随诊断测试的开发是两条平行的路径，彼此紧密相连，能够更快地为合适的患者提供合适的治疗。我们与艾德生物的合作可以通过加速创新治疗药物和伴随诊断试剂的开发，进一步提升药品可及性，为改善患者的治疗效果而努力。” 伴随诊断试剂通过检测患者中的预测性生物标志物，识别出可能对治疗有良好反应的患者亚群。此次合作展示了施维雅不断为全球患者提供更好的精准医疗服务的雄心。 #ServierChina #Glioma #Patient #Oncology

We are pleased to share the latest progress of Vorasidenib in China. Recently, Vorasidenib has obtained the approval for clinical trial (III) from National Medical Products Administration (NMPA). The clinical trial is a multicenter, randomized, double-blind, placebo-controlled study of Vorasidenib in Asian subjects with residual or recurrent grade 2 glioma with IDH1 or IDH2 mutations. Vorasidenib is an oral, selective, highly brain-penetrant dual inhibitor of mutant isocitrate dehydrogenase 1 and 2 (IDH1/2) enzymes for the treatment of IDH-mutant diffuse glioma. Therapeutic progress in the low-grade glioma space has been stagnant for decades. We hope Vorasidenib will offer a potential breakthrough for those eagerly awaiting a new therapeutic option in China. 施维雅已获得中国国家药品监督管理局核准签发的《药物临床试验批准通知书》，在携带IDH1或IDH2突变的残留或复发性2级胶质瘤亚洲受试者中开展Vorasidenib的III期、多中心、随机、双盲、安慰剂对照研究。 Vorasidenib是一款口服、选择性、高度脑渗透性的双重抑制剂，针对突变型异柠檬酸脱氢酶1和2（IDH1和IDH2），可用于治疗携带IDH突变的弥漫性胶质瘤。低级别胶质瘤治疗领域的创新已经停滞了数十年。我们希望Vorasidenib能够惠及那些迫切等待全新治疗选择的中国患者。 #ServierChina #Glioma #Patient #Oncology

In #ServierChina, we are very proud to develop and manufacture our medicines locally. From brand-name drugs local manufacturing to supply chain management, Servier Tianjin Plant is certificated for all stages of the medicine life cycle. This means that we can provide the safe and high-quality medicines to patients in China, addressing the needs in cardiovascular metabolism, venous diseases, and oncology. #ServierMoments of today. It's from Renzhe ZHANG of Engineering Department, sharing his working diary behind the busy production line. He is one of us, ensuring safe operation, as well as high-quality and on-time delivery with passion, dedication and professional spirit. 在施维雅中国，我们非常自豪能够在本地开发和生产自己的药品。从原研药本地化生产到供应链合作管理，施维雅天津生产基地可以实现药品的全生命周期管理。这确保我们始终为广大中国患者提供安全和高质量的药品，满足心血管代谢、静脉健康与肿瘤领域的治疗需求。 #关于施维雅人的vlog ，让我们一起来了解工程部张仁喆的分享，在天津生产基地繁忙生产线幕后工作日常，以热情投入、专注专业的职业精神，确保安全平稳运转和高质量按时交付。 #WeAreServier #WeAreIndustry #MovedByYou #45yearsAnniversary

#ServierMoments of today. Under the program organized by #MécénatServier, Servier's global Charity Fund, SHUORAN FU from Servier China HR team shared her two weeks of volunteer experience in Tonle Sap lake in Cambodia. SHUORAN is the first volunteer from #ServierChina providing onsite support for the people lived in a floating village. She did not only brought knowledge and experience to the people, but also pass on confidence, friendship and hope to them. Let's check out what SHUORAN is going to say!   #MécénatServierCharityFund contributes to meeting the Group’s social responsibility challenges and embodies its convictions as a corporate citizen. It has supported more than 50 initiatives around the world since its inception in 2016.    #关于施维雅人的vlog ，来自HR团队的付铄然分享了她参加施维雅慈善基金会的项目，深入洞里萨湖水上社区两周的志愿者经历。铄然是施维雅中国第一位为居住在浮村的人们提供现场支持的志愿者。她不仅为当地人带去经验和知识，而且向他们传递了信心、友爱与希望。让我们一起去了解这段独特的经历吧!   施维雅慈善基金（Mécénat Servier）为施维雅集团的社会责任做出了贡献，体现了其企业公民的信念。自2016年成立以来，施维雅慈善基金在世界各地支持了50多个公益项目。   #WeAreServier #MovedByYou #45yearsAnniversary #SheIsServier

Every year this time is to talk about #WorldHypertensionDay. Globally, hypertension is a driving force in the epidemic of non-communicable diseases and is the leading risk factor for death and disability globally. In China, the prevalence of hypertension is 23.2%, with an estimated number of people affected reaching 245 million. As a leader in cardiometabolism, Servier is committed to sharing blood pressure screenings tips and education on lifestyle modification that help reduce the risk for stroke, cardiovascular disease, and kidney disease. Under the theme "Measure Your Blood Pressure Accurately, Control It, Live Longer!", we launched #BecauseISaySo (BISS) public awareness campaign, which has been carried out continuously in China for six years in a row. Let's work together to promote awareness of high blood pressure and accuracy in blood pressure measurement! 每一年的今天是世界高血压日。 在全球范围内，高血压是一种发病率很高的慢行非传染性疾病，也是全球死亡和残疾的主要风险因素。 在中国，高血压患病率为23.2%，预计患病人数达到2.45亿。 作为心脏代谢领域的领导者，施维雅致力于分享血压筛查技巧和改变生活方式的教育，帮助降低中风、心血管疾病和肾脏疾病的风险。 在“精准测量，有效控制，健康长寿”这一主题下，我们再次启动#BecauseSaySo（BISS） 公益活动，该活动已在中国连续开展了六年时间。让我们一起努力，提高防治高血压的意识，掌握精准测量血压的方法，迈向更健康的生活。 #WeAreServier #MovedByYou #TherapeuticArea